Background: Systematic reviews (SRs) have shown that clinical decision support
Worldwide, approximately 415 million adults suffer from diabetes, and the numbers are projected to rise to 552 million by 2040. 1 In the United States, costs related to diabetes were estimated at $174 billion in 2007, with most of this cost arising from personal expenditures, drugs, health care services, and lost productivity at work. 2 Diabetes is associated with diminished quality of life, disabling complications, high health care costs, and reduced life expectancy. 3 A challenge faced by decision makers in management of diabetes is that, in many instances, there is a persistent gap between recommended care guidelines and current practice. 4 For the treatment of diabetes, achievement of target glucose levels is difficult because physicians have no benchmark to make decisions about whether to start, continue, or adjust insulin doses or injections. 5 Therefore, an obvious gap exists between actual clinical practice and optimal patient care. 6 The need for cost-effective improvements in managing and treating diabetes is evidently important.
Currently, the American Diabetes Association has realized that this situation and action have been taken to improve the health care of patients with diabetes. 7 Clinical decision support systems (CDSSs) have been promoted as a promising approach that targets safe and effective diabetes management. 8 A CDSS is a computerized system that uses case-based reasoning to assist clinicians in assessing disease status, in making a diagnosis, in selecting appropriate therapy, or in making other clinical decisions. 9 Characteristics of individual patients are matched to a computerized knowledge base, and software algorithms generate patient-specific information in the form of assessments or recommendations. 10 It is reported that treatment of diabetes is a complex undertaking for clinicians, which may be simplified and improved by CDSS. 11 CDSS is used to promote diabetes care by facilitating evidence-informed insulin use, improving control of blood glucose, and improving quality indicators in caring for patients with diabetes. 12 Until now, several systematic reviews (SRs) have summarized the effects of CDSS on diabetes. 11, [13] [14] [15] [16] Nirantharakumar and Jeffery systematically assessed the impact of CDSS on diabetes in noncritical care 11 and ambulatory care setting. 14 Two SRs synthesized the evidence of CDSS with type 2 diabetes, 13, 16 and one focused on gestational diabetes mellitus. 15 These SRs suggested that CDSS has potential for improving diabetes care. However, the role of CDSS within mainstream diabetes care remains controversial. One of the most important arguments against their use has been that methodological and reporting qualities of published CDSS SRs is unknown and these quality flaws could affect the integrity and accuracy of research. In view of these limitations, it is questionable whether diabetes patients benefit from CDSS interventions. To ensure that patients receive effective medical treatment, determining the reliability of current SR evidence and methodological areas in need of improvement is crucial. This will also prevent future use of flawed methodology.
Therefore, we innovatively conducted an overview of CDSS on diabetes. 17 The purpose of our study was to comprehensively assess the effects of CDSS on diabetes, to evaluate methodological and reporting qualities in this field, and to provide suggestions for methodological quality improvement. 
| Quality assessment
The Assessment of Multiple Systematic Reviews (AMSTAR) was used to evaluate methodological quality. 20 For each SR, quality of reporting against the 11 items was determined as "Yes," "Partially yes," "No,"
"Can't answer," or "Not applicable," allocating 1 point if the SR met that requirement for a specific item, 0.5 if the item was partially met, or 0 if the item was not met, was unclear, or was not applicable. 20 The possible score of the AMSTAR was 0 to 11. The final scores were summed and ranked on a 3-category criterion used by Beverley and Jeremy: low quality (score between 0 and 4), medium quality (score between 5 and 8), and high quality (score between 9 and 11). 21 The reporting quality assessment was based on the Preferred
Reporting Items for Systematic reviews and Meta-Analyses (PRISMA). 22 To indicate the degree of compliance, each checklist item was assigned 1 of 4 responses: "Yes" for total compliance, "partial" for partial compliance, "No" for noncompliance, and "NA" for not applicable. 23 Two authors (P.L.J. and P.J.Z.) performed independent data extraction and quality assessment from each selected SR. Uncertainties or discrepancies were resolved by discussion or through consultation with the senior author (M.M.Z.) if agreement could not be reached.
| Data analysis
Our overview was conducted fundamentally according to the guidelines referenced in version 5.1.0 of the Cochrane Handbook for Systematic Reviews of Interventions. 18 Mean differences, standard deviations, and standardized mean differences were used for continuous variables, and dichotomous variables were presented as odds ratios or rate ratios. If the SRs provided sufficient data and comparable outcomes, a meta-analysis was considered. If the outcome data were not appropriate for a meta-analysis, the outcome was described narratively based on the interventions and outcome.
3 | RESULTS
| Search results
We identified 9303 studies based on our initial search. (Table 3 ).
| Reporting quality
Overall, none of the included 17 SRs fulfilled all 27 items of PRISMA.
The "data items," "summary of evidence," and "conclusions" were well described across all SRs; of the included 17 SRs, total compliance with CONSORT items was more than 80.0% in "study selection" (item 9, 88.2%), "summary measures" (item 13, 94.1%), "synthesis of results"
(item 14, 88.2%), "study selection" (item 7, 82.4%), "study characteristics" (item 18, 94.1%), and "synthesis of results" (item 21, 94.1%).
Items with markedly incomplete reporting were "structured abstract"
(item 2, 11.1%), "protocol and registration" (item 5, 17.6%), "data collection process" (item 10, 17.6%), and "risk of bias across studies" (item 15, 11.8%; Table 4 ).
| Synthesis of evidence
A meta-analysis was not performed because of the heterogeneity in the included studies. We presented the results in narrative and tabular (Table 2 ).
| DISCUSSION
To our knowledge, this is the first overview that concentrated on assessing the effects of CDSS on diabetes, which is important for health care, and specifically diabetes-related complications. Furthermore, our overviews creatively assessed the quality of SRs on the effectiveness of CDSS interventions using AMSTAR and PRISMA.
Considering the important roles of methodological and reporting qualities for judging the true effects of interventions, our study will add to the body of knowledge to determine whether a computerized program would facilitate better diabetes care.
Consistent with previous reviews, our study found that CDSS may improve diabetes care by impacting the process of care or patient outcomes. 4, 29 The improvement of patient outcomes is critical because these outcomes directly reflect the quality of diabetes care. However, changes in process of care outcomes is also important. The integration of CDSS into clinical practices generated better results for process of care outcomes (increasing HbA1c testing rates, frequency of provider visits, and eye exam rates), and this in itself may provide indirect evidence of the improvement of diabetes care. 34 Therefore, the influence of CDSS on diabetes care may be direct or indirect. Although an intermediary outcome, changes in keeping with best practice guidelines would be expected to deliver better diabetes care, even if direct evidence was not found in these studies.
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FIGURE 1 Flow chart for search and selection processes 
Abbreviations: Y, Yes; P, Partially yes; N, No; CA, Can't answer; NA, Not applicable.
TABLE 4
The results of reporting quality assessment 
| Synthesis of systematic review results
Based on our synthesis, most SRs (82%) measured process of care outcomes and results suggested that use of CDSS would improve outcomes. Our study found that CDSSs aimed at providing alerts or reminders to participants were most likely to impact diabetes care by improving participant activity, such as frequency of provider visits or eye exams, proportion of women who underwent an OGTT, or utilization time of website. Similar findings were reported by a number of published studies. 4, 26, 33 These studies demonstrated that CDSSs have an impressive impact on participant activity with recommended diabetes care guidelines. 29 An explanation for this might be the fact that the CDSS encompasses a wide range of automatic computerized tools directed at improving diabetes care, including automatic reminders and advice. 8 A metaregression analysis showed that automatic provision of CDSS was a critical feature of successful change in participant behavior. 35 The implementation of automated or personalized reminders, which are relatively convenient interventions and easy to adopt by provider practices, is very helpful in improving appointment making and participant behaviour. 33 However, while 88% of the included studies measured a patient outcome, only a small proportion (31%) demonstrated positive findings. This situation was true in the related studies. 4, 14, 16 This may be attributed to the small sample sizes 19 and short-term nature of the original studies. 36 Our study also found that CDSSs providing feedback on performance, reminders, and alerts were most likely to improve diabetes care by impacting patient outcomes. Providing feedback and prompting behaviour seem to be critical elements of behaviour change for both physicians and patients. 13 Moreover, patient outcomes such as death and bleeding complications will be influenced by factors other than better physician behaviour. 34 A metaregression of CDSS showed that provision of advice to both physicians and patients prompted the success of such systems.
Therefore, maximizing improvements in patient outcomes may require CDSS interventions designed to change behaviour in both clinicians and patients. nitive, behavioural, and emotional outcomes. 29 For this to happen, specialized and diversely designed CDSS needs to be implemented.
These factors combined made it impossible to pool results. Therefore, it is likely that heterogeneity exists in this field and the heterogeneous nature of the interventions made the traditional meta-analysis impossible. Another main methodological issue is that the blinding processes
were not adequate in all of the included studies. Participant and intervention-provider blinding is often not feasible in complex interventions, such as CDSS. As reported by Walton 37 and Gillaizeau, 38 the same health care professional may have given treatment both to intervention and control groups. As such, it is possible that the CDSS influenced the treatment of the control groups. As a result, contamination of the control group would tend to make it harder to detect a real effect of CDSS. 19 
| Reporting quality
Across those 17 SRs, no obvious increasing trend in reporting quality was visible over the years, with regard to fulfilment of the PRISMA checklist. This was attributable to the small sample sizes of our study that were consequently underpowered. 19 Our study found that less than half of the PRISMA items were completely reported in a typical trial, with a concerning gap in the reporting of several items. Items related to the methodological domains, such as type of risk of bias within studies and risk of bias across studies, were particularly incomplete. Considering that both the methodological and reporting qualities are important for judging the overall strength of evidence on given research questions, 39 the incomplete reporting of methodological domains may jeopardize health care professionals and clinicians ability to make judgments on SR value.
| STRENGTHS AND LIMITATIONS
One of the key strengths of our study is that it was the first study to systematically and comprehensively assess the effectiveness of CDSS interventions on diabetes care. Secondly, we innovatively assessed the quality of SRs on the effectiveness of CDSS interventions using AMSTAR and PRISMA. Thirdly, we conducted a comprehensive search, developed explicit eligibility criteria, and applied rigorous methods for screening studies and collecting data.
Our study also has some weaknesses. Firstly, we were unable to use quantitative analysis to pool effect sizes, given the heterogeneity among the included SRs. Secondly, we considered the results on 3 levels by grading them on the strength of evidence for improvement.
The methods, together with the rigorous inclusion criteria, may have underestimated the effects of CDSS intervention.
| CONCLUSIONS
Clinical decision support systems improved the quality of diabetes care by inconsistently improving process of care or patient outcomes.
There is evidence that CDSS for providing alerts, reminders, or feedback to the participants was most likely to impact diabetes care. The poor reporting of the methodological domains, together with the qualitative or narrative methods to combine the findings, may limit the confidence of research evidence. As with any health care innovation, CDSS should be rigorously evaluated before its widespread dissemination into clinical practice.
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